½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting

  • »¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

    021-54845833/15800441009

    Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

    µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > Íÿ¹DDIT4L¶à¿Ë¡¿¹Ìå

    ²úÆ·ÖÐÐÄ

    ×îвúÆ·

    • Íÿ¹DDIT4L¶à¿Ë¡¿¹Ìå

      ¹æ¸ñ£º
      ¼Û¸ñ£º£¤
      • Æ·ÅÆ : ͨεÉúÎï
      • Ŀ¼ºÅ : TW17865
      • Ó¦Óà : ½ö¹©¿ÆÑÐʹÓÃ
      • »õÆÚ : ÏÖ»õ
      • ¹æ¸ñ £º100ul/200ul/25ul
    • ÉÌÆ·ÏêÇé
    • ²Î¿¼ÎÄÏ×
    • ˵Ã÷ÊéÏÂÔØ
    • ÉÌÆ·ÆÀÂÛ0
    • Ïà¹Ø²úÆ·


    ÖÐÎÄÃû³Æ£ºÍÿ¹DDIT4L¶à¿Ë¡¿¹Ìå 

    Ó¢ÎÄÃû³Æ£º Anti-DDIT4L rabbit polyclonal antibody

    ±ð      Ãû£º REDD2; Rtp801L

    Ïà¹ØÀà±ð£º Ò»¿¹

    ¿¹      Ô­£º DDIT4L

    ´¢      ´æ£º Àä¶³£¨-20¡æ£©

    ËÞ      Ö÷£º Rabbit

    ·´Ó¦ÖÖÊô£º Human, Mouse, Rat

    ±ê  ¼Ç Î Unconjugate

    ¿Ë¡ÀàÐÍ£º rabbit polyclonal

    ¼¼Êõ¹æ¸ñ

    Background:

    REDD-2 (regulated in development and DNA damage response 2), also designated Rtp801L or DDIT4L (DNA-damage-inducible transcript 4-like), is a 193 amino acid cytoplasmic protein belonging to the DDIT4 family and is predominantly expressed in skeletal muscle. Considered a stress-inducted protein, REDD-2 is a negative regulator of the mTOR (mammalian target of rapamycin) pathway. mTOR is a serine/threonine kinase that plays an essential role in cell growth control and is an important regulator of skeletal muscle size. Highly expressed in human atherosclerotic lesions and macrophages, REDD-2 mediates monocyte cell death through reduction of Trx (thioredoxin-1) expression. REDD2 expression in macrophages increases oxidized LDL (oxLDL)-induced cell death, suggesting that REDD2 may play a critical role in arterial pathology.

    Applications:

    ELISA, IHC

    Name of antibody:

    DDIT4L

    Immunogen:

    Fusion protein of human DDIT4L

    Full name:

    DNA-damage-inducible transcript 4-like

    Synonyms£º

    REDD2; Rtp801L

    SwissProt:

    Q96D03

    ELISA Recommended dilution:

    1000-2000

    IHC positive control:

    Human thyroid cancer

    IHC Recommend dilution:

    25-100





    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿


    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿